Long-acting 2-adrenoceptor agonists: increased risk of death?

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1072, 2005-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Some Pharmacodynamic Aspects on Long-Acting -Adrenoceptor Agonists

By Waldeck B.

General Pharmacology, Vol. 27, Iss. 4, 1996-06 ,pp. : 575-580

Elsevier

Access to resources Recommend Favorite

Effect of short- and long-acting 2 -adrenoceptor agonists on pulmonary 2 -adrenoceptor expression in human lung

By Nishikawa M. Mak J.C.W. Barnes P.J.

European Journal of Pharmacology, Vol. 318, Iss. 1, 1996-12 ,pp. : 123-129

Elsevier

Access to resources Recommend Favorite

Long-acting β₂ agonists

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. : 99-104

Informa Healthcare

Access to resources Recommend Favorite

Long-acting -agonists not linked to increased respiratory deaths

Reactions Weekly, Vol. 1, Iss. 1202, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Long-Acting 2-Adrenoceptor Agonists and Exercise-Induced Asthma: Lessons to Guide Us in the Future

By Anderson Sandra D. Brannan John D.

Pediatric Drugs, Vol. 6, Iss. 3, 2004-01 ,pp. : 161-175

Adis International

Access to resources Recommend Favorite